The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”.

The FDA has so far approved four botanical products, with a view to greenlight more. Credit: Svetliy/Shutterstock.com. The US Food and Drug Administration (FDA) is requesting public input on both the ...

The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.